Logo
x

Search

Subscribe Now

Janssen

Janssen Reports the CHMP’s Positive Opinion of Balversa (Erdafitinib) to Treat Metastatic Urothelial Carcinoma (mUC)

Janssen Reports the CHMP’s Positive Opinion of Balversa (Erdafitinib) to Treat Metastatic Urothelial Carcinoma (mUC)

  • June 28, 2024
Janssen Submits a Marketing Authorisation Application to the EMA for Lazertinib Plus Rybrevant to Treat Lung Cancer

Janssen Submits a Marketing Authorisation Application to the EMA for Lazertinib Plus Rybrevant to Treat Lung Cancer

  • December 23, 2023
PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

  • October 14, 2023
Janssen Reports P-IIIb Study (ESCAPE-TRD) Results of Spravato (esketamine nasal spray) for Treatment-Resistant Major Depressive Disorder

Janssen Reports P-IIIb Study (ESCAPE-TRD) Results of Spravato (esketamine nasal spray) for Treatment-Resistant Major Depressive Di...

  • October 10, 2023
Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung C...

  • September 29, 2023
Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC at IASLC 2023 WCLC

Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC...

  • September 12, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.